distribution agreement with clinical medical m, page-16

2. I don't know what Oraline 8 will sell for but my understanding is that the cost base is not much greater than that for Oraline iv (which is price competitive) so there would be heaps of pricing flexibility here. Can't see that as a problem

Yeah. My understanding is that it is a single immunoassay membrane, and once the tech for that is sorted, the actual cost of the device and packaging is not any different. So whilst retail of the OraLine VIII device would no doubt be higher (if they continue to sell the OraLine IV), the actual cost to the company would be very modest (not taking into account the R&D involved).

So, if they can ramp up production and sales, OraLine VIII could be very profitable.

Cheers